**Statins in cirrhosis – ready for prime time**

<table>
<thead>
<tr>
<th>Journal:</th>
<th>Hepatology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>HEP-17-0794.R1</td>
</tr>
<tr>
<td>Wiley - Manuscript type:</td>
<td>Editorial</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>n/a</td>
</tr>
<tr>
<td>Complete List of Authors:</td>
<td>Tschochatzis, Emmanuel; Royal Free Hospital, The Royal Free Sheila Sherlock Liver Centre and UCL Institute of Liver and Digestive Health; Bosch, Jaime; Hepatic Hemodynamic Laboratory, Liver Unit Hospital Clinic, IDIBAPS and Ciberehd</td>
</tr>
<tr>
<td>Keywords:</td>
<td>portal hypertension, decompensation, prognosis, ascites, variceal bleeding</td>
</tr>
</tbody>
</table>
Statins in cirrhosis – ready for prime time

Emmanuel A. Tsochatzis¹, Jaime Bosch²,³

1. UCL Institute for Liver and Digestive Health and Sheila Sherlock Liver Unit, Royal Free Hospital and UCL, London, UK.

2. Hepatic Hemodynamic Laboratory, Hospital Clínic-IDIBAPS and CIBERehd, University of Barcelona, Spain.

3. Swiss Liver Center, Inselspital, Bern University, Switzerland.

Corresponding author: Emmanuel A. Tsochatzis (e.tsochatzis@ucl.ac.uk) or Jaime Bosch (jbosch@clinic.cat)
Statins are inhibitors of the HMG-CoA reductase with lipid-lowering properties that are routinely prescribed for primary and secondary prevention of cardiovascular events (1). In recent years, experimental and observational studies have demonstrated that statins have pleiotropic effects over and above their anti-lipid mechanism of action, and have been proposed as part of potential preventative strategies for decompensation in cirrhosis (1).

There is a strong experimental rational for such strategies. From a mechanistic perspective, simvastatin increases nitric oxide (NO) availability in the cirrhotic liver circulation by enhancing the expression and activity of endothelial NO-synthase and therefore ameliorates portal hypertension, but also prevents endothelial dysfunction during endotoxaemia (2). An anti-inflammatory effect is achieved through a decreased production of inflammatory cytokines and leukocyte migration to the sub-endothelial space. Importantly, mainly mediated by upregulation of the nuclear receptor KLF2, statins have anti-fibrotic effects due to inhibition of hepatic stellate cell activation by its paracrine interaction with endothelial sinusoidal cells (3).

In their article in Hepatology, Chang and co-authors used the Taiwan National Health Insurance database in a nested case-control study to estimate the effect of statins on the risk of decompensation, mortality and HCC in patients with cirrhosis. Index cases of cirrhosis were identified from a representative sample of 1,000,000 people who were followed from 2000 to 2013 (4). The authors used propensity score matching and finally selected 675 patients with cirrhosis in each of the statin-user and non-statin user group from a potential size of 1172 statin users. HCV, HBV and alcohol were the included aetiologies of cirrhosis. Statin users were defined as cirrhotic patients with more than 28 cumulative
defined daily dose (cDDD) of any statin. Statin users and non-users were well matched in baseline characteristics including the Charlson comorbidity index. Use of statins was associated with a significantly lower risk of decompensation (HR 0.39), mortality (HR 0.46) and HCC development (HR 0.52) in a dose-response relationship in the overall cirrhotic population, with users with a cDDD>365 days having the greatest benefit. When analysed according to the aetiology of cirrhosis, statin use was associated with a reduced risk of decompensation in HBV and HCV and a trend for lower risk of decompensation in ALD, but no change in the risk of mortality or HCC in independent aetiologies (likely due to lower number of patients/events in this sub analysis).

An advantage of this study compared to other population studies is that it derives from a well-validated general population database, thus significantly reducing the risk of selection bias. There are inevitable weaknesses as with such retrospective analyses, which include the lack of patients with NASH cirrhosis, the absence of laboratory parameters (with ensuing inability to calculate and correct for the MELD and Child-Pugh score), a potential lead-time bias for the incident HCC cases and the low threshold (cDDD>28) to classify a patient as statin user. Nevertheless, the propensity score matching was robust and non-bleeding varices at baseline was added in the model to account for the presence of clinically significant portal hypertension. The dilution of the statin effect in individual aetiologies of cirrhosis is most likely due to type II error rather than selective effectiveness in viral hepatitis over alcohol-induced cirrhosis.

This study adds further observational evidence on the potential beneficial effects of statins in patients with cirrhosis. In large cohort studies, statin use was protective against significant fibrosis in patients with NAFLD (5) and was
associated with approximately 50% lower risk of progression to cirrhosis in patients with HCV (6) and HBV (7). In a cohort of 40,512 patients with compensated HCV cirrhosis, statin use was associated with a 40% lower risk of decompensation and death (8). Statins have also been associated with reduced risk for the development of hepatocellular carcinoma in various liver disease aetiologies (1). Importantly, these studies suggest that such effects are class effects rather than related to a particular statin and apply to all non-cholestatic aetiologies of cirrhosis. However, even promising, these studies need confirmation by prospective randomized clinical trials (RCTs).

There have been two proof of concept prospective RCTs on the use of statins for cirrhosis so far. In a RCT of 59 patients, simvastatin given for one month significantly reduced portal pressure by an average of 8.3% and was associated with a marked improvement in liver indocyanine-green clearance, indicating a potential for improved liver function (9). Importantly, the effect on portal pressure was over and above that of non-selective beta-blockers. In a further RCT in 158 patients with decompensated cirrhosis due to previous variceal bleeding, addition of simvastatin to standard of care was independently associated with a survival benefit (HR=0.55) in those patients with Child Pugh A and B cirrhosis (10). The study is an important guidance to further study design; although the primary composite endpoint of reduction of rebleeding or death was not achieved, simvastatin had a significant effect in all cause mortality, mostly due to less bleeding or infection-related deaths, further reinforcing the pleiotropic statin effect (10). This is in keeping with data from pre-clinical cirrhotic models showing that statins protect from liver failure secondary to sepsis and hypovolemic shock (2). In the BLEPS study, statins were no beneficial
in patients with Child-Pugh C cirrhosis (10). Moreover, there were 2 cases of statin-induced rhabdomyolysis in Child-Pugh C patients compared to no cases in Child Pugh A or B thus raising efficacy and safety concerns in patients with more advanced liver disease. Figure 1 shows the potential beneficial effects of statins in the evolution of cirrhosis and combines the presented data.

The above evidence justifies a phase III RCT of statins in patients with cirrhosis. Such a trial should only include compensated patients with Child-Pugh A (and potentially Child Pugh B7) with the primary endpoint being a composite outcome of decompensation or death. Given the fact that most statins are inexpensive and generic drugs, public funding would be required. In an era of increasingly expensive medications with profound impact on healthcare budgets, exploring the repurposing of statins for cirrhosis is a too good opportunity to be missed.


Figure 1. Potential impact of statins on the evolution of chronic liver disease. Transition from chronic liver disease to compensated cirrhosis is driven by fibrogenesis, while progression from compensated to decompensated cirrhosis is mainly driven by complications of portal hypertension. Both disease drivers may be attenuated or prevented by statins. Statins may also prevent further decompensation due to sepsis and to gastrointestinal bleeding, however there is an efficacy and safety concern in patients with Child Pugh C.

HCC: hepatocellular carcinoma; SBP: spontaneous bacterial peritonitis
Chronic Liver Disease → Compensated Cirrhosis → Decompensated Cirrhosis → Death

Clinical Manifestations:
- asymptomatic
- asymptomatic
- ascites, bleeding, encephalopathy, infections
- rebleeding, ascites, SBP

Statins → fibrogenesis → portal hypertension → HCC

Statins → HCC

Statins → Death

Statins

HCC

Hepatology

Page 9 of 9